Get the Stockscreener App
0.604
0.00%
0.00
Silo Pharma Inc stock is traded at $0.604, with a volume of 110.54K.
It is up +0.00% in the last 24 hours and up +24.97% over the past month.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
See More
Previous Close:
$0.604
Open:
$0.5976
24h Volume:
110.54K
Relative Volume:
0.15
Market Cap:
$4.23M
Revenue:
$72,100
Net Income/Loss:
$-3.60M
P/E Ratio:
-0.5076
EPS:
-1.19
Net Cash Flow:
$-3.37M
1W Performance:
+2.37%
1M Performance:
+24.97%
6M Performance:
-26.52%
1Y Performance:
-37.08%
1-Day Range:
$0.5624
$0.5976
1-Week Range:
$0.5614
$0.6199
52-Week Range:
$0.4101
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Name
Silo Pharma Inc
Sector
Industry
Phone
(718) 400-9031
Address
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4495 | 544.73M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.67 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1485 | 318.66M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.71 | 118.42M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.883 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Stock (SILO) Latest News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
SILO Pharma Secures USPTO Approval for Key Patent Enhancing SPC-15 Protection | SILO Stock News - GuruFocus
Silo Pharma receives patent allowance for PTSD treatment technology - Investing.com
Silo Pharma receives patent allowance for PTSD treatment technology By Investing.com - Investing.com Canada
Silo Pharma, Inc. Receives Notice of Allowance for Patent Strengthening SPC-15 Treatment for PTSD - Nasdaq
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - GlobeNewswire
Breakthrough PTSD Drug Patent: Silo Pharma's Intranasal Treatment Advances Toward Clinical Trials - Stock Titan
Silo Pharma approves purchase of Bitcoin as treasury reserve asset; shares up - MSN
Silo Pharma allocates $1 million to Bitcoin holdings By Investing.com - Investing.com South Africa
Is Silo Pharma moving to BIO Protocol? No - Binance
Silo Pharma's Board Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset; Shares Rise - marketscreener.com
Silo Pharma (SILO) Allocates $1 Million for Bitcoin Investment | - GuruFocus
Silo Pharma allocates $1 million to Bitcoin holdings - Investing.com
Silo Pharma stock surges on Bitcoin reserve move - Investing.com
Silo Pharma stock surges on Bitcoin reserve move By Investing.com - Investing.com South Africa
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset - The Manila Times
Silo Pharma, Inc. Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset - Nasdaq
Biotech Makes Bold Move: Silo Pharma Commits $1M to Bitcoin as Inflation Shield - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s - simplywall.st
Silo Pharma advances PTSD treatment with new drug-device study By Investing.com - Investing.com South Africa
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 - GlobeNewswire
Silo Pharma stock plunges to 52-week low of $0.47 By Investing.com - Investing.com Canada
Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug - Seeking Alpha
SiloPharma (SILO) Advances SPC-15 with New Drug-Device Study Agreement | SILO Stock News - GuruFocus
Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15 - marketscreener.com
Silo Pharma advances PTSD treatment with new drug-device study - Investing.com Australia
Breakthrough PTSD Treatment: Silo Pharma's Brain-Targeting Drug Delivery System Heads to FDA - Stock Titan
Silicon Valley - FinancialContent
Silo Pharma Announces Closing of $2 Million Public Offering - GlobeNewswire
Silo Pharma Completes Public Offering, Raises $1.56 Million - TipRanks
Silo Pharma, Inc. Completes Public Offering Raising Approximately $2 Million - Nasdaq
Silo Pharma Announces Closing Of $2 Million Public Offering - marketscreener.com
SEC Form 424B4 filed by Silo Pharma Inc. - Quantisnow
Silo Pharma sets public offering at $0.60 per share and warrant - Investing.com Nigeria
SiloPharma (SILO) Sets $2 Million Public Offering with Warrants - GuruFocus
Silo Pharma Announces Pricing of $2 Million Public Offering - The Manila Times
Silo Pharma, Inc. Prices Public Offering of 3,333,338 Shares with Associated Warrants - Nasdaq
Silo Pharma Announces $2M Offering with 5-Year Warrants: Complete Details of Latest Financing Round - Stock Titan
Silo Pharma advances in PTSD nasal therapy trials By Investing.com - Investing.com Canada
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment - Asianet Newsable
Silo Pharma (SILO) Partners with Veloxity Labs for Key Drug Stud - GuruFocus
Silo Pharma advances PTSD treatment study with Veloxity Labs By Investing.com - Investing.com Canada
Silo Pharma (SILO) Partners with Veloxity Labs for Key Drug Study | SILO Stock News - GuruFocus
Silo Pharma advances PTSD treatment study with Veloxity Labs - Investing.com Australia
Silo Pharma Inc Stock (SILO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Silo Pharma Inc Stock (SILO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Dec 13 '24 |
Buy |
0.84 |
2,500 |
2,097 |
187,932 |
| Weisblum Eric | CEO and President |
Nov 20 '24 |
Buy |
0.95 |
2,500 |
2,375 |
182,932 |
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):